Skip to main content
. Author manuscript; available in PMC: 2013 Apr 2.
Published in final edited form as: Mol Pharm. 2012 Mar 13;9(4):979–985. doi: 10.1021/mp200614q

Figure 5.

Figure 5

Figure 5

Figure 5

Figure 5

Cytokine levels (day 55) from splenocytes of mice treated subcutaneously with solution Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-NH2-2-NP, or Blank-NP. (A) In the Ac-PLP-BPI-NH2-2-NP-treated group, IL-6 cytokine levels were significantly lower than in the groups treated with Ac-PLP-BPI-NH2-2 (#, p < 0.005) and Blank-NP (*, p < 0.05). (B) In the Ac-PLP-BPI-NH2-2- and Ac-PLP-BPI-NH2-2-NP-treated groups, IL-17 cytokine levels were significantly lower than in the group treated Blank-NP (*, p < 0.05). (C) In the Ac-PLP-BPI-NH2-2-NP-treated group, IFNγ cytokine levels were significantly lower than in the groups treated with Ac-PLP-BPI-NH2-2 (#, p < 0.005) and Blank-NP (*, p < 0.05). (D) In the Ac-PLP-BPI-NH2-2-NP-treated group, IL-2 cytokine levels were significantly lower than in the group treated with Ac-PLP-BPI-NH2-2 (#, p < 0.0005). On the other hand, IL-2 production was higher in the Ac-PLP-BPI-NH2-2-treated group than in the negative control (p < 0.05). (E) No significant difference in IL-4 production was observed between any of the groups (p > 0.05). (F) In the Ac-PLP-BPI-NH2-2-NP-treated group, IL-5 cytokine levels were significantly lower than in the groups treated with Ac-PLP-BPI-NH2-2 (#, p < 0.0005) and Blank-NP (*, p < 0.0005).